Product Images Gemfibrozil

Gemfibrozil Tablets are medication that must be stored at controlled room temperature between 20°C to 25°C (68°F to 77°F). They are dispensed in tight containers that are child-resistant. Each tablet contains 600 mg of gemfibrozil. These tablets are manufactured by Ascent Pharmaceutics and are available in a pack of 1000 as a prescription-only medicine. It is recommended to check the package insert for full prescribing information before use. The medication should be protected from light and humidity.*

This appears to be a list of potential side effects associated with a medication that affects the central nervous system. Some of the side effects listed include cholestatic jaundice, dizziness, blurred vision, decreased libido, and bone marrow hypoplasia. The text also notes a potential causal relationship with laryngeal edema and peripheral neuritis. It is important to note that this text alone does not provide any information about what medication is being referred to, and caution should always be exercised when taking any medication.*

This text provides a comparison between the frequency of adverse reactions reported in a group of 2046 subjects receiving Gemfibrozil versus a group of 2035 subjects receiving a placebo treatment. The data shows that Gemfibrozil patients reported higher frequencies of gastrointestinal reactions, dyspepsia, abdominal pain, acute appendicitis, and atrial fibrillation than those taking placebo treatment. However, adverse events like diarrhea, fatigue, nausea/vomiting, eczema, rash, vertigo, constipation, and headache did not show any significant differences between the two groups.*

This is a table showing the reduction in coronary heart disease rates in patients over a 5-year period based on their baseline lipid levels. The table displays the number of events per 1000 patients and the difference in rates between the placebo and gemfibrozil groups. The lipid values at baseline for the patients are shown in mg/dL. The events considered in the study include fatal and non-fatal myocardial infarctions and sudden cardiac deaths.*

The table shows the number of cardiac events and all-cause mortality per 1000 patients during the 3.5 year open-label follow-up to the Helsinki Heart Study. The data is grouped based on the original randomization (placebo or gemfibrozil) and drug taken during follow-up (N=attend clinic but took no drug, G=gemfibrozil, or Drop=no attendance at clinic). The table includes data for 215, 494, 1283, 221, 574, and 1207 patients.*

This is a table titled "Cardiac Events, Cardiac Deaths, Non-Cardiac Deaths, and All-Cause Mortality in the Helsinki Heart Study, Years 0-8.5." It compares the effects of Gemfibrozil and placebo on Cardiac Events, Cardiac Deaths, Non-Cardiac Deaths, and All-Cause Mortality. The table includes data on Event numbers, Hazard ratios, Cardiac Deaths, Non-Cardiac Deaths, and All-Cause Mortality, and their corresponding values for Gemfibrozil and Placebo. It is an analysis of the originally randomized patients neglecting the open-label treatment switches and exposure to study conditions.*